March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Pharmacokinetics and Biodistribution of Bevacizumab Following Suprachoroidal Injection into the Rabbit Eye Using a Microneedle
Author Affiliations & Notes
  • Saffar Mansoor
    Chemical & Biomolecular Engineering, Georgia Institute of Technology, Atlanta, Georgia
  • Samikrumar R. Patel
    Chemical & Biomolecular Engineering, Georgia Institute of Technology, Atlanta, Georgia
  • Cetin Tas
    Pharmaceutical Sciences, Gulhane Military Academy, Ankara, Turkey
  • Rashmi Pacha-Ravi
    Pharmaceutical Sci & Ophthal, University of Colorado Denver, Aurora, Colorado
  • Uday B. Kompella
    Pharmaceutical Sci & Ophthal, University of Colorado Denver, Aurora, Colorado
  • Henry F. Edelhauser
    Ophthalmology, Emory Univ Eye Center, Atlanta, Georgia
  • Mark R. Prausnitz
    Chemical & Biomolecular Engineering, Georgia Institute of Technology, Atlanta, Georgia
  • Footnotes
    Commercial Relationships  Saffar Mansoor, None; Samikrumar R. Patel, 12/767/768 (P), Clearsdie Biomedical (I); Cetin Tas, None; Rashmi Pacha-Ravi, None; Uday B. Kompella, None; Henry F. Edelhauser, None; Mark R. Prausnitz, 12/767,768 (P), Clearside Biomedical (I)
  • Footnotes
    Support  NEI grant R24 EY017404
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 498. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Saffar Mansoor, Samikrumar R. Patel, Cetin Tas, Rashmi Pacha-Ravi, Uday B. Kompella, Henry F. Edelhauser, Mark R. Prausnitz; Pharmacokinetics and Biodistribution of Bevacizumab Following Suprachoroidal Injection into the Rabbit Eye Using a Microneedle. Invest. Ophthalmol. Vis. Sci. 2012;53(14):498.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : As an alternative to intravitreal injection, this study presents injection of bevacizumab into the suprachoroidal space (SCS) using a hollow microneedle. This minimally invasive approach deposits bevacizumab between the sclera and choroid, which targets drug delivery to its therapeutic site of action. The purpose of this study is to quantify the pharmacokinetics and biodistribution of bevacizumab in the rabbit eye. This is the first study to assess bevacizumab delivery in vivo after injection into the SCS using a microneedle.

Methods: : Bevacizumab (Avastin®, 1250 µg/50 µl) was injected into the SCS of pigmented rabbits using a metal microneedle measuring 700-800 µm in length inserted 5 mm posterior to the limbus. Rabbits were euthanatized and eyes were enucleated at 15 min, 1 day, and 2 days following SCS injection. Ocular tissues (sclera, choroid, retina, aqueous humor, vitreous, anterior tissues, lens and optic nerve) were separated. Bevacizumab was then extracted from these tissues and quantified using ELISA.

Results: : The percent bevacizumab recovered from the eyes was 88.4±0.9% at 15 min, 4.6±0.5% at 1 day, and 0.2±0.1% at 2 days after injection. The distribution of bevacizum in ocular tissues at 15 min after injection was 76% in choroid, 13% in sclera and 2.9% in retina, 1.0% in vitreous, 0.5% in aqueous humor, 0.9% in anterior chamber, 0.6% in lens and 0.1% in optic nerve. After 1 day, drug levels were 34% in choroid, 27% in sclera and 23% in retina, 11% in vitreous, 0.7% in aqueous humor, 1.6% in anterior chamber, 3.8% in lens and 0.3% in optic nerve. After 2 days, the distribution of bavacizum was 0.5% in choroid, 3.3% in sclera, 0.5% in retina, 55% in vitreous, 3% in aqueous humor, 36% in anterior chamber, 1.1% in lens and 0.6% in optic nerve.

Conclusions: : A microneedle was able to inject bevacizumab into the SCS of rabbit eyes using a minimally invasive procedure. There was a quick biodistribution of bevacizumab into choroid, sclera, and retina, indicating excellent drug targeting. However, choroidal levels of bevacizumab declined very rapidly. The current formulation of bevacizumab is therefore not optimal and a sustained-release formulation of bevacizumab may be needed to achieve sustained delivery to the posterior segment of the eye.

Keywords: choroid: neovascularization • retina • vascular endothelial growth factor 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×